Why the study?
Heart disease in SLE is linked to increased morbidity and mortality, yet whether traditional coronary artery disease treatments significantly impact mortality in this population remains unclear.
Answers are grounded in this paper and cite their sources.
This review provides a comprehensive overview of the diverse cardiac manifestations of systemic lupus erythematosus and their management.
Systemic lupus erythematosus (SLE) is a complex connective tissue disease that can potentially affect every organ of the human body. In some cases, SLE may present with diverse cardiac manifestations including pericarditis, myocarditis, valvular disease, atherosclerosis, thrombosis, and arrhythmias. Heart disease in SLE is associated with increased morbidity and mortality. It is unclear whether traditional treatments for coronary artery disease significantly impact mortality in this population. Current therapeutic agents for SLE include glucocorticoids, hydroxychloroquine, mycophenolate mofetil, azathioprine, methotrexate, cyclophosphamide, and B cell-directed therapies. This article will provide a comprehensive review and update on this important disease state.
No takes yet. Share an insight, caveat, or question.
Linares-Koloffon et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: